Table 4. Mortality and neurodevelopmental findings at 18 to 22 months in infants assigned to placebo group according to subsequent clinical steroid use (adjusted analysis).
| Variable | Placebo Steroid | Placebo No Steroid | RR (95% CI) | p-value |
|---|---|---|---|---|
| No. / total No. (%) | ||||
| Primary outcome | ||||
| Death or NDI | 31/45(69) | 30/47(64) | 0.85(0.64,1.13) | 0.27 |
| Specific outcomes in survivors | ||||
| Moderate to severe cerebral palsy | 7/39(18) | 1/29(3) | 2.58(0.20,33.2) | 0.47 |
| Bayley MDI <70 | 15/34(44) | 10/28(36) | 1.12(0.55,2.27) | 0.75 |
| Bayley PDI <70 | 16/34(47) | 6/28(21) | 1.78(0.70,4.50) | 0.22 |
| NDI | 20/34(59) | 11/28(39) | 1.22(0.65,2.31) | 0.53 |
| Abnormal neurologic exam | 16/39(41) | 1/29(3) | 11.02(1.21,100.33) | 0.03 |
NDI = Neurodevelopmental impairment (moderate/severe cerebral palsy, MDI or PDI less than 70, blindness or hearing impairment). MDI = Mental developmental index; PDI = Psychomotor developmental index; RR is the relative risk of the outcome in the placebo group treated with steroid as compared with the placebo group that did not receive steroid. CI denotes confidence interval. Not adjusted for center due to convergence issues.